OBJECTIVES: Although largely asymptomatic, nonalcoholic steatohepatitis (NASH) can lead to an increased risk of liver cirrhosis and hepatocellular carcinoma. Improved early detection of NASH can result in reducing a substantial societal burden. Current guidelines suggest the presence of NASH when the patient has a nonalcoholic fatty liver disease (NAFLD) Activity Score (NAS) of 3 or above. NAS score therefore plays an integral role in determining the size of the current NASH population. This study sought to identify the frequency and predictors of NAS measurement. METHODS:  Data from Ipsos’ NASH Therapy Monitor were analysed; the NASH Therapy Monitor is a retrospective medical chart review of NAFLD patients in the US, fielded from September to November 2016. N=174 physicians provided patient demographics, disease status, comorbidities, testing, and treatment data on their most recent 5-10 NAFLD patients. Clinical and economic outcomes were reported descriptively; logistic regression models were conducted to identify factors associated with the likelihood of a complete NAS measurement. RESULTS:  1396 NASH patients (57% male; mean age 51.7 years [SD = 12.0], mean BMI=35.0 [SD=9.1]) were included in our analysis. Only 52% of these patients had a complete NAFLD Activity Score (NAS), i.e. steatosis (69%), lobular inflammation (61%) and hepatocyte ballooning (61%) measured. The strongest predictors of a complete NAS measurement [at p<.05] were NAFLD fibrosis scores indicating advanced liver fibrosis (odds ratio [OR]=4.2), Medicare B insurance (OR= 2.8), male (OR=2.0), lack of concomitant disorders (OR=1.7), and type 2 diabetes (OR=1.5). Obesity was not associated with a complete NAS measurement. CONCLUSIONS:  Only half of patients had NAS measurements with elevated NAFLD scores and Medicare B insurance the strongest predictors. As NASH-specific treatment options become available, a greater focus on NAS measurement could have clinical and economic implications by allowing for earlier intervention prior to the onset of disease complications.